- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01542892
Efficacy of Nutritional Supplementation on Physical-activity Mediated Changes in Physical Functioning Older Adults at Risk for Mobility Disability (The VIVE2 Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Exercise Intervention: Participants will complete exercise sessions 3 times per week for 6 months. The exercise sessions will involve walking, lower extremity strength exercises, flexibility, and balance training.
Supplement Intervention: Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.
Primary Outcome: The primary outcome will be the time to walk 400 meters, expressed as average gait speed during the 400 M walk. All participants must be able to walk 400 meters in <15 minutes at walking at their normal speed. The 400 M walk will be assessed at baseline, 3-months, and 6-months, with the changes at 6-months being the primary outcome.
Secondary Outcome Measures:
- Stair Climb Test
- Body Composition
- Skeletal muscle cross sectional area
- Isokinetic/Isometric peak torque/power
- Hand-grip strength
- Nutritional status
- Quality of Life/Depressive symptoms Expected enrollment: 150 (80 at Tufts University (Boston, MA, USA), 70 at University of Uppsala (Uppsala, Sweden))
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Uppsala, Sweden, 75185
- Uppsala University
-
-
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Jean Mayer Human Nutrition Research Center on Aging at Tufts University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male & Female ≥ 70 yrs
- Community dwelling
- Short Physical Performance Battery ≤ 9
- Willingness to be randomized and come to the laboratory for 6 months
- Body Mass Index < 35
- Mini-Mental State Examination >=24
- Serum 25 (OH) D (22.5 -50 nmol/l)
- Having obtained his/her informed consent
- Able to complete 400 M walk within 15 minutes
Exclusion Criteria:
• Acute or terminal illness; terminal illness with life expectancy less than 12 months, as determined by a physician
- Current regular use (> 1 per week) of high protein oral nutritional supplements (eg: Boost, Exceed etc…)
- Current use of Vitamin D supplements, >800 IU/day
- Myocardial infarction in previous 6 months, symptomatic coronary artery disease, or congestive heart failure.
- Upper or lower extremity fracture in previous 6 months.
- Hemoglobin < 10 g/dL, Estimated GFR < 30 mL/min/1.73 m2
- Uncontrolled hypertension (>150/90 mm Hg).
- Neuromuscular diseases and drugs which affect neuromuscular function; severe progressive, degenerative neurologic disease
- Hormone replacement therapy
- Insulin-dependent diabetes mellitus
- Milk protein allergy
- Major surgery in the past 6 months (requiring general anesthesia)
- Other significant co-morbid disease that would impair ability to participate in the exercise-based intervention, e.g. renal failure on hemodialysis, severe psychiatric disorder (e.g. bipolar, schizophrenia)
- Excessive alcohol use (>14 drinks per wk)
- Participation in moderate intensity physical activity > 20 minutes/week
- Inability to communicate due to severe, uncorrectable hearing loss or speech disorder
- Severe visual impairment (if it precludes completion of assessments and/or intervention)
- Severe rheumatologic or orthopedic diseases, e.g., awaiting joint replacement, active inflammatory disease; wheelchair bound
- Cancer requiring treatment in the past three years, except for non-melanoma skin cancers or cancers that have clearly been cured or in the opinion of the investigator carry an excellent prognosis (e.g., Stage 1 cervical cancer)
- Severe pulmonary disease, requiring either steroid pills or injections or the use of supplemental oxygen
- Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina
- Patient who cannot be expected to comply with treatment, as decided by the Principal Investigator and study physician.
- Conditions not specifically mentioned above may serve as criteria for exclusion at the discretion of the clinical site Principal Investigator and/or study physician.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Exercise
|
Participants will complete exercise sessions 3 times per week for 6 months.
The exercise sessions will involve walking, lower extremity strength exercises, flexibility, and balance training.
|
|
EXPERIMENTAL: Supplement
|
Participants will be randomly assigned to receive either the nutritional supplement or placebo.
The participants will consume on beverage immediately after each exercise session.
|
|
SHAM_COMPARATOR: Placebo
|
Participants will be randomly assigned to receive either the nutritional supplement or placebo.
The participants will consume on beverage immediately after each exercise session.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Walk 400 meters
Time Frame: 6-Month
|
The primary outcome will be the time to walk 400 meters, expressed as average gait speed during the 400 M walk.
All participants must be able to walk 400 meters in <15 minutes at walking at their normal speed.
The 400 M walk will be assessed at baseline, 3-months, and 6-months, with the changes at 6-months being the primary outcome.
|
6-Month
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Roger Fielding, PhD, Tufts University
Publications and helpful links
General Publications
- von Berens A, Fielding RA, Gustafsson T, Kirn D, Laussen J, Nydahl M, Reid K, Travison TG, Zhu H, Cederholm T, Koochek A. Effect of exercise and nutritional supplementation on health-related quality of life and mood in older adults: the VIVE2 randomized controlled trial. BMC Geriatr. 2018 Nov 21;18(1):286. doi: 10.1186/s12877-018-0976-z.
- Englund DA, Kirn DR, Koochek A, Zhu H, Travison TG, Reid KF, von Berens A, Melin M, Cederholm T, Gustafsson T, Fielding RA. Nutritional Supplementation With Physical Activity Improves Muscle Composition in Mobility-Limited Older Adults, The VIVE2 Study: A Randomized, Double-Blind, Placebo-Controlled Trial. J Gerontol A Biol Sci Med Sci. 2017 Dec 12;73(1):95-101. doi: 10.1093/gerona/glx141. Erratum In: J Gerontol A Biol Sci Med Sci. 2019 Nov 13;74(12):1993.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10.27.CLI
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcopenia
-
Cairo UniversityNot yet recruitingGeriatric SarcopeniaEgypt
-
University Hospital, BonnRecruiting
-
Shanghai Yueyang Integrated Medicine HospitalShanghai University of Traditional Chinese Medicine; DongE E Jiao Coporation... and other collaboratorsNot yet recruiting
-
Assiut UniversityNot yet recruiting
-
TNF Pharmaceuticals, Inc.Not yet recruitingFrailty | Sarcopenia in Elderly | Frailty/Sarcopenia | Frailty in Older Adults
-
University of ExtremaduraCompletedSarcopenia in Elderly | Institutionalized Older Adults | HIITSpain
-
Animuscure Inc.Recruiting
-
West China HospitalNot yet recruitingSarcopenia in Elderly
-
Centre Hospitalier Universitaire DijonCompleted
-
Medway NHS Foundation TrustNot yet recruitingFalls | Sarcopenia in ElderlyUnited Kingdom
Clinical Trials on Supplement Intervention
-
Vanderbilt UniversityAgency for Healthcare Research and Quality (AHRQ)Completed
-
University of ThessalyRecruitingMultiple Sclerosis | Anemia | IBD | Colitis Ulcerative | Hypertension (HTN)Greece
-
Huashan HospitalRecruiting
-
University Hospital OstravaRecruitingCritical Illness | Prolonged Mechanical VentilationCzechia
-
Yonsei UniversityCompleted
-
ENBIOSIS BIOTECHNOLOGIESAydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi Demirsoy... and other collaboratorsRecruitingType 2 Diabetes | Diabetes Mellitus Type 2Turkey (Türkiye)
-
Henrik GudbergsenUnknownObesity | OsteoarthrtisDenmark
-
German Institute of Human NutritionGerman Diabetes CenterUnknownObesity | Diabetes Mellitus Type 2 | NAFLD | Prediabetes | DyslipoproteinemiaGermany
-
Hacettepe UniversityCompletedCaffeine | L-theanine | EsportsTurkey
-
Wake Forest University Health SciencesNational Institute on Aging (NIA)CompletedObesity | Weight Loss | Diet Modification | Aging | Dietary Habits | Weight Change, BodyUnited States